Journal of Clinical Oncology, Vol 16, 3524-3527, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study

J Treat, E Johnson, C Langer, C Belani, B Haynes, R Greenberg, R Rodriquez, P Drobins, W Miller Jr, L Meehan, A McKeon, J Devin, R von Roemeling and J Viallet
Allegheny University of the Health Sciences, Hahnemann Division, Philadelphia, PA 19104, USA.

PURPOSE: A phase II study was conducted to evaluate the safety and efficacy of tirapazamine combined with cisplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. RESULTS: Ten of 44 patients (23%) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25%), fatigue (27.3%), and muscle cramps (4.5%). No dose reductions were necessary. CONCLUSION: The results show that tirapazamine can safely be added to cisplatin. Both the median survival and response rate observed strongly suggest that tirapazamine with cisplatin is more active than cisplatin alone.

This article has been cited by other articles:

				R L Cowen, E J Garside, B Fitzpatrick, M V Papadopoulou, and K J Williams Gene therapy approaches to enhance bioreductive drug treatment Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S45 - S56. [Abstract] [Full Text] [PDF]

				S. K. Williamson, J. J. Crowley, P. N. Lara Jr, J. McCoy, D. H.M. Lau, R. W. Tucker, G. M. Mills, and D. R. Gandara Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003 J. Clin. Oncol., December 20, 2005; 23(36): 9097 - 9104. [Abstract] [Full Text] [PDF]

				Q.-T. Le, J. McCoy, S. Williamson, J. Ryu, L. E. Gaspar, M. J. Edelman, S. R. Dakhil, S. D. Sides, J. J. Crowley, and D. R. Gandara Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): A Southwest Oncology Group Study Clin. Cancer Res., August 15, 2004; 10(16): 5418 - 5424. [Abstract] [Full Text] [PDF]

				M. V. Papadopoulou and W. D. Bloomer NLCQ-1 (NSC 709257): Exploiting Hypoxia with a Weak DNA-Intercalating Bioreductive Drug Clin. Cancer Res., November 15, 2003; 9(15): 5714 - 5720. [Abstract] [Full Text] [PDF]

				P. N. Lara Jr., P. Frankel, P. C. Mack, P. H. Gumerlock, I. Galvin, C. L. Martel, J. Longmate, J. H. Doroshow, H. J. Lenz, D. H. M. Lau, et al. Tirapazamine Plus Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors: A California Cancer Consortium Phase I and Molecular Correlative Study Clin. Cancer Res., October 1, 2003; 9(12): 4356 - 4362. [Abstract] [Full Text] [PDF]

				L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Shasha Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes Oncologist, December 1, 2002; 7(6): 492 - 508. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and K. Kelly New Combinations in the Treatment of Lung Cancer : A Time for Optimism Chest, April 1, 2000; 117(4_suppl_1): 138S - 143S. [Abstract] [Full Text] [PDF]

				J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler, V. Hirsh, et al. Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group J. Clin. Oncol., March 13, 2000; 18(6): 1351 - 1359. [Abstract] [Full Text] [PDF]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]